Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

被引：3
|
作者：
Gunther, Jillian R. [1 ]
Pinnix, Chelsea C. [1 ]
Glober, Gordon R. [2 ]
Christopherson, Kaitlin M. [1 ]
Fang, Penny [1 ]
Lee, Hun Ju [3 ]
Ahmed, Sairah [3 ]
Steiner, Raphael E. [3 ]
Nair, Ranjit [3 ]
Strati, Paolo [3 ]
Neelapu, Sattva S. [3 ]
Nastoupil, Loretta J. [3 ]
Dabaja, Bouthaina S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 97,1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Univ Cent Florida, Coll Med, Orlando, FL USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
来源：
EJHAEM | 2020年 / 1卷 / 01期
基金：
美国国家卫生研究院;
关键词：
chemotherapy; Hodgkins lymphoma; radiotherapy; RADIATION PNEUMONITIS; OLDER; DACARBAZINE; HD13;
D O I：
10.1002/jha2.1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de-escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early-stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen was not found to be noninferior; however, the effect of partial omission is unknown. We investigated the effect of bleomycin omission on outcome for 150 early-stage HL patients. At 8 years, freedom from relapse was 99% for both patients who received complete or incomplete bleomycin, which is reassuring for patients requiring bleomycin omission due to toxicity.
引用
收藏
页码：272 / 276
页数：5
相关论文
共 50 条
  • [1] Partial Omission of Bleomycin for Early Stage Hodgkin Lymphoma Patients Treated with Combined Modality Therapy: Does Incomplete ABVD Lead to Inferior Outcomes?
    Gunther, J. R.
    Pinnix, C. C.
    Glober, G.
    Christopherson, K. M.
    Lee, H.
    Ahmed, S.
    Steiner, R. E.
    Nair, R.
    Strati, P.
    Neelapu, S. S.
    Nastoupil, L.
    Dabaja, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E476 - E477
  • [2] Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma
    Torok, Jordan A.
    Wu, Yuan
    Chino, Junzo
    Prosnitz, Leonard R.
    Beaven, Anne W.
    Kim, Grace J.
    Kelsey, Chris R.
    ANTICANCER RESEARCH, 2018, 38 (05) : 2875 - 2881
  • [3] Combined modality treatment for early-stage Hodgkin lymphoma: The GHSG experience
    Engert, A.
    Diehl, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 16 - 16
  • [4] Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A realworld study.
    Chohan, Karan
    Young, Jason R.
    Lester, Scott
    Moustafa, Muhamad Alhaj
    Rosenthal, Allison Claire
    Tun, Han W.
    Hoppe, Bradford
    Johnston, Patrick B.
    Micallef, Ivana N. M.
    Habermann, Thomas Matthew
    Ansell, Stephen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy
    Filippi, Andrea Riccardo
    Botticella, Angela
    Bello, Marilena
    Botto, Barbara
    Castiglione, Anna
    Gavarotti, Paolo
    Gottardi, Daniela
    Parvis, Guido
    Bisi, Gianni
    Levis, Alessandro
    Vitolo, Umberto
    Ricardi, Umberto
    LEUKEMIA & LYMPHOMA, 2013, 54 (06) : 1183 - 1187
  • [6] An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma
    Hay, A. E.
    Klimm, B.
    Chen, B. E.
    Goergen, H.
    Shepherd, L. E.
    Fuchs, M.
    Gospodarowicz, M. K.
    Borchmann, P.
    Connors, J. M.
    Markova, J.
    Crump, M.
    Lohri, A.
    Winter, J. N.
    Doerken, B.
    Pearcey, R. G.
    Diehl, V.
    Horning, S. J.
    Eich, H. T.
    Engert, A.
    Meyer, R. M.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3065 - 3069
  • [7] Chemotherapy or combined modality therapy for early-stage Hodgkin lymphoma: A comparative, population-based study.
    Shrestha, Rajesh
    Castillo, Jorge J.
    Olszewski, Adam J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma
    Jhawar, Sachin R.
    Rivera-Nunez, Zorimar
    Drachtman, Richard
    Cole, Peter D.
    Hoppe, Bradford S.
    Parikh, Rahul R.
    JAMA ONCOLOGY, 2019, 5 (05) : 689 - 695
  • [9] Presence of risk factors does not affect outcome in early stage pediatric Hodgkin lymphoma treated with ABVD
    Bhethanabhotla, Sainath
    Bakhshi, Sameer
    ANNALS OF HEMATOLOGY, 2017, 96 (03) : 521 - 522
  • [10] Presence of risk factors does not affect outcome in early stage pediatric Hodgkin lymphoma treated with ABVD
    Sainath Bhethanabhotla
    Sameer Bakhshi
    Annals of Hematology, 2017, 96 : 521 - 522
12345